Teal and white drug capsules falling onto surface

Scientists identified non-antibiotic drugs that can act as antibiotics to prevent development of bacterial drug resistance.

credit: iStock/solarseven

The bacteria-fighting skills of non-antibiotic drugs

Researchers identified existing medications that target novel pathways in E. coli, offering a potential solution to the growing antibiotic resistance threat.
Adam Boros, PhD
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

While antibiotics revolutionized medicine, their overuse led to bacteria developing resistance, rendering the drugs ineffective for some cases. Scientists now urgently search for new ways to combat bacterial infections.

Amir Mitchell from the University of Massachusetts instructing graduate student on bacterial cultures and antibiotic resistance.
Amir Mitchell (left), leads a research group at the University of Massachusetts where he works with coauthor Mariana Noto (right).
CREDIT: Amir Mitchell

Researchers at the University of Massachusetts led by cancer biologist Amir Mitchell, wondered if non-antibiotic drugs might also have antibacterial potential (1). By screening anticancer drugs for antibacterial effects, the researchers identified new bacterial targets for antibiotics, opening the potential for new treatments in the fight against infections. 

“We started off doing some work on trying to understand the toxicity of different chemotherapies on bacteria,” Mitchell said. “This led us to a bigger question of how many drugs that were never designed to be antibiotics were impacting bacteria.” 

Deciphering how non-antibiotic drugs harm bacteria could be a medical game-changer. If they target bacteria differently than standard antibiotics, they offer exciting possibilities for new antibiotic development. However, if they work similarly to existing drugs, their long-term use in chronic illnesses might unintentionally contribute to antibiotic resistance. 

Mitchell’s team used pooled genetic screening of an Escherichia coli strain collection and high-throughput barcode gene sequencing to analyze almost two million instances of toxicity between 200 drugs and thousands of bacteria with single gene deletions. They used a machine learning algorithm to group the drugs based on how they killed the bacteria. The analysis showed that known antibiotics grouped together by their known classes of killing mechanisms, and non-antibiotic drugs formed separate hubs from antibiotics, indicating that non-antibiotic and antibiotic drugs have different ways of killing bacterial cells.

Traditional antibiotics often work by interfering with cell wall synthesis, protein production, or DNA replication (2). In contrast, the non-antibiotic drugs identified in the study disrupted various other bacterial functions such as translation initiation. Because non-antibiotics affect different bacterial pathways compared to conventional antibiotics, bacteria are less likely to develop resistance to non-antibiotic drugs. 

Network analysis of antibiotic drugs represented by colored shaped and non-antibiotics represented by black or grey shapes demonstrate that non-antibiotics do not cluster with antibiotic drugs.
In the network representation across all drugs, antibiotic drugs of the same class (colored circles) cluster together, illustrating their shared modes of action. However, most of the non-antibiotic drugs fall outside of these clusters, which indicates that they operate via different mechanisms.
CREDIT: Mariana Noto

The team then investigated whether they could identify new drug targets in bacteria using non-antibiotic drugs. They grew hundreds of generations of bacteria exposed to different non-antibiotic drugs. The group then sequenced the genomes of the bacteria that adapted to the drugs and applied their machine learning algorithm. 

This approach pinpointed the specific bacterial proteins targeted by different non-antibiotic drugs. For example, they identified a bacterial protein targeted by triclabendazole, a drug used to treat parasite infections. Currently available antibiotics don’t target this protein, highlighting the potential of machine learning approaches to identify drugs with unknown bacteria-killing mechanisms.

“You really need an efficient method to quickly tell you the mechanisms of action,” said Mitchell.  “AI gives you a way out of this to develop new applications,'' he added. “We are at the watershed moment in history. Everything is going to change.”

Joao Xavier, a bioinformatician from the Memorial Sloan Kettering Cancer Center who was not part of this study, said, “This is a type of work with very modern principles of analyzing drug effects on bacteria at a very broad scale while looking at the impact of every single gene and their interactions with a vast library of molecules. It's really the type of work that we need to advance our understanding of novel antibiotics.”

Mitchell and his group now plan to test if the non-antibiotic drugs they identified can serve as useful antibiotics in animal models and human samples. “For us, the most exciting thing is really pushing the envelope and increasing the throughput of the research we can do,” Mitchell said.

References 

  1. Noto Guillen, M., Li, C., Rosener, B. & Mitchell, A. Antibacterial activity of nonantibiotics is orthogonal to standard antibiotics. Science  384, 93–100 (2024).
  2. Halawa, E. M. et al. Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Front Pharmacol  14, (2024).

About the Author

  • Adam Boros, PhD
    He earned his MSc and PhD degrees from the Faculty of Medicine at the University of Toronto and has extensive writing experience in the pharmaceutical industry.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue